Home > Insider Trading > Filing (0001192482-21-000405)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1372299	Ocugen Inc.	OCGN	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1791822	Vijay Tammara	C/O Ocugen, Inc. 263 Great Valley Parkway Malvern PA 19355	Senior Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-05-04	4,900	$0.46	4,900	No	4	M	Direct
Common Stock	Disposition	2021-05-04	4,900	$13.81	0	No	4	S	Direct
Common Stock	Acquisiton	2021-05-04	2,000	$2.94	2,000	No	4	M	Direct
Common Stock	Disposition	2021-05-04	2,000	$13.81	0	No	4	S	Direct
Common Stock	Acquisiton	2021-05-04	6,500	$0.51	6,500	No	4	M	Direct
Common Stock	Disposition	2021-05-04	6,500	$13.50	0	No	4	S	Direct
Common Stock	Acquisiton	2021-05-04	2,311	$0.57	2,311	No	4	M	Direct
Common Stock	Disposition	2021-05-04	2,311	$13.81	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options (Right to Buy)	Disposition	2021-05-04	4,900	$0.00	4,900	$0.46
Common Stock	Options (Right to Buy)	Disposition	2021-05-04	2,000	$0.00	2,000	$2.94
Common Stock	Options (Right to Buy)	Disposition	2021-05-04	6,500	$0.00	6,500	$0.51
Common Stock	Options (Right to Buy)	Disposition	2021-05-04	2,311	$0.00	2,311	$0.57

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2024-09-18	No	4	M	Direct
2,191	2026-04-26	No	4	M	Direct
58,261	2030-01-02	No	4	M	Direct
42,578	2030-08-14	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.35 to $13.71. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
All of the options became exerciable immediately upon grant.
The option, initially representing a right to purchase a total of 77,641 shares, vests and becomes exercisable annually in equal installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates.
The option, initially representing a right to purchase a total of 50,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on September 14, 2020, subject to continued service with the Company on the applicable vesting dates.